Lv3
305 积分 2021-08-20 加入
Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence
2天前
已完结
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
1个月前
已完结
MA02.07 Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation
2个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
2个月前
已完结
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
2个月前
已完结
Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant NSCLC
2个月前
已关闭
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
3个月前
已完结
“The RAS Dam Has Broken”
3个月前
已完结
An overview of KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities
3个月前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
3个月前
已完结
皖公网安备34019202002308
